The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.

ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...

The White House withdrew Dr. Dave Weldon's nomination as CDC director just before his Senate hearing. His vaccine safety ...

Q4 2024 Earnings Call Transcript March 11, 2025 Operator: Welcome to the SIGA Business Update Call. Before we turn the call ...

Two hundred and fifteen cases of mpox infection were reported to Santé publique France in 2024. Tecovirimat is the drug most commonly used to treat patients infected with the mpox virus. Unfortunately ...

While these studies did not show statistical significance difference between tecovirimat and placebo at this primary endpoint, the PALM 007 results did signal potential benefits for patients ...